Roads & Highways company IRB Infrastructure Developers announced Q2FY26 results Total Income: Rs 1,800 crore against Rs 1,752 crore during Q2FY25, change 3%. EBITDA: Rs 974 crore against Rs 933 crore during Q2FY25, change 4%. PBT: Rs 261 crore against Rs 267 crore during Q2FY25, change -2%. PAT: Rs 141 crore against Rs 100 crore during Q2FY25, change 41%. Virendra D. Mhaiskar, Chairman & Managing Director, said: “The first half of the year, particularly Q2, continued to demonstrate strong momentum in toll revenue growth, despite a severe and extended monsoon period. We have also successfully completed the sale of three assets, in line with our B.E.S.T. (Bid, Execute, Stabilize, Transfer) strategy of efficient asset churn and sustainable growth without any dilution. This has enabled us to unlock approximately Rs 5,000 crore of equity in the Private InvIT, positioning us to pursue further opportunities of around Rs 15,000 crore in the sector. These developments keep us firmly on track to achieve an asset base of Rs 1.4 trillion over the next three years.” “This robust performance strengthens our confidence that growth will further accelerate in the coming quarters, supported by the ongoing pace of consolidation”. Result PDF
Conference Call with Container Corporation of India Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with PI Industries Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Agrochemicals company PI Industries announced Q2FY26 results Revenue: Rs 18,723 million against Rs 22,210 million during Q2FY25, change -16%. EBITDA: Rs 5,434 million against Rs 6,289 million during Q2FY25, change -14%. EBITDA Margin: 29% for Q2FY26. Net Profit: Rs 4,093 million against Rs 5,082 million during Q2FY25, change -19%. Result PDF
Biotechnology company Biocon announced Q2FY26 results Operating Revenue for Q2FY26 grew 20% YoY to Rs 4,296 crore. Core EBITDA at Rs 1,218 crore, grew 23% with core operating margins of 28%. Net R&D; investments for the quarter were Rs 251 crore, representing 7% of revenue ex-Syngene. EBITDA for the quarter at Rs 928 crore, grew by 29 % with an EBITDA margin of 21%. Profit Before Tax before exceptional items stood at Rs 183 crore, an increase of 153%. Net Profit for the quarter, before exceptional items, stood at Rs 92 crore with a growth of 579%. Reported Net Profit for the quarter stood at Rs 85 crore, up 428%. Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said: “Business performance in Q2FY26 remained strong, with operating revenue up 20% year-onyear to Rs 4,296 crore, driven by robust growth in Biosimilars, improved momentum in Generics, and a steady contribution from the CRDMO segment. EBITDA grew 29% to Rs 928 crore, while Profit before Tax (PBT), excluding exceptional items, surged 153% to Rs 183 crore. “With the Board approval of the settlement of structured debt obligations, we will strengthen our balance sheet, enhance financial flexibility, and improve profitability. “Our partnership with the State of California through Civica Inc. under the CalRx initiative, marks a landmark step in expanding affordable insulin access in the U.S., with potential to extend to other states. “With a resilient foundation, differentiated portfolio, and clear strategy, we are well positioned to sustain growth and deliver long-term value to our stakeholders.” Siddharth Mittal, CEO & Managing Director, Biocon, said: “The Generics business continued its steady performance in Q2 with a growth of 24% driven primarily by an uptick in recently launched products in the U.S. and EU, as well as growth in the generic formulations base business, and the API business. “A key highlight of this quarter was the inauguration of Biocon’s first OSD manufacturing facility in the United States, a significant step towards expanding access to our vertically integrated portfolio for patients in the region. We commenced filings for Semaglutide (gOzempic) in various markets, including Canada and Brazil.” Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: “Biocon Biologics delivered a strong performance in Q2 FY26, achieving 25% year-on-year revenue growth and an over 40% increase in EBITDA. Sequentially, revenues grew 11%, driven by market share expansion in key therapy areas and successful new product launches. In the U.S., we continue to expand access to biosimilars by leveraging the strength of our commercial platform. In FY26, we launched four biosimilars across key global markets and remain on track for the bDenosumab launch.” Peter Bains, CEO & Managing Director, Syngene International, said: “Our Q2 results reflect strong underlying revenue growth in research services, which has offset the expected inventory correction in biologics manufacturing. We continue to maintain our annual guidance for FY26. “We are also building a GMP bioconjugation suite at our Bengaluru biologics facility, which will enable end-to-end manufacturing of Antibody Drug Conjugates (ADCs), positioning us among a select group of CRDMOs offering comprehensive ADC services.” Result PDF
Conference Call with Max Financial Services Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Fortis Healthcare announced Q2FY26 results Consolidated Revenues at Rs 2,331 crore, up 17.3% YoY. Operating EBITDA Margin at 23.9% vs 21.9% in Q2FY25. Profit after Tax at Rs 329 crore, up 70.3% YoY. Hospital Business Revenues at Rs 1,974 crore, up 19.3% YoY. Operating EBITDA margin at 22.9% vs 21.4% in Q2FY25. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said: “We have maintained a healthy growth momentum across both our hospital and diagnostics businesses. In the hospital segment, key specialties such as Oncology and Renal Sciences grew by 29% and 22%, respectively, compared to the same period last year. Our growth and expansion strategy is accelerating on multiple fronts. The company recently entered into a lease agreement for a ~200-bedded multi-specialty hospital in Greater Noida, a facility that we had previously been managing under an O&M; arrangement. This expands our presence in Delhi NCR to ~2,100 beds. The integration of Gleneagles units under the O&M; arrangement with Fortis is progressing well and we have also made our foray in Lucknow with an O&M; arrangement for a 550 bedded super specialty hospital to be constructed by the Ekana Group.” “In the diagnostics business, we continue to witness a buoyant recovery in both revenue and EBITDA margin and expect this positive momentum to continue going forward.” Result PDF